Press Releases

Everest Medicines Announces Interim Results for First Half of 2024

Everest Medicines Announces Attendance at the Following September Investor Conferences

Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16

Everest Medicines to Announce 2024 Interim Results on August 28, 2024

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Everest Medicines' Partner Calliditas Announces an Additional Efficacy Analysis of NEFECON® at the 61st European Renal Association Congress

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients

Everest Medicines’ Partner Calliditas Announces Positive NefIgArd Open Label Extension Results

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023

Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Everest Medicines’ Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis